Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One of them had to do with Citadel's position in the pharmaceutical giant Eli Lilly (NYSE: LLY). Ken Griffin and his team ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Eli Lilly stock has advanced ... revenue climbed 20%, showing Lilly's other products are also contributing to growth. So Lilly isn't dependent on just one or two products, and that's positive.

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...